−0.001 BRL
−2.20 B BRL
9.13 B BRL
About Alnylam Pharmaceuticals, Inc.
Sector
CEO
Yvonne L. Greenstreet
Headquarters
Cambridge
Website
Founded
2002
ISIN
BRA1LNBDR003
FIGI
BBG00XV4BP79
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Displays a symbol's price movements over previous years to identify recurring trends.
ALNY5653584
Alnylam Pharmaceuticals, Inc. 1.0% 15-SEP-2027Yield to maturity
−2.37%
Maturity date
Sep 15, 2027
Explore more bonds
Curated watchlists where A1LN34 is featured.